With this 100% online program, you will acquire competencies in the identification and analysis of disease patterns, the implementation of outbreak prevention strategies and the management of health emergencies”

The COVID-19 pandemic has underscored the critical importance of robust, real-time surveillance systems that enable early detection of outbreaks and rapid implementation of control measures. At the same time, international cooperation and data sharing have become essential to address global health threats. 

This is how this program was created, which will provide pharmacists with an in-depth understanding of the fundamental principles of health protection and prevention. In this way, epidemiological surveillance, risk assessment, management, control and communication will be covered, providing essential tools for professional practice. In addition, self-control and surveillance systems will be examined through hazard analysis and identification of critical control points. 

The epidemiology and risk factors associated with diseases such as Cancer and Cardiovascular Diseases, as well as their primary and secondary prevention, will also be analyzed. Likewise, a solid basis for the detection of rare diseases and the implementation of neonatal screening programs will be provided. 

Finally, the ability of professionals to identify and describe the main components of intervention studies, evaluating their quality and methodology will be developed. Pharmacists will also be able to analyze pragmatic and explanatory clinical trials, including the different phases of the design of diagnostic test validity studies. Without overlooking the importance of quality and methodological correctness in studies of prognostic factors, also introducing patient safety as a key concept in health care. 

Therefore, an online program of excellent quality has been designed to meet the individual needs of students and eliminate the associated problems, such as moving to a physical campus and adapting to fixed schedules. Additionally, a revolutionary learning methodology called Relearning has been integrated, which involves the review of essential concepts to achieve a more solid understanding of the contents. 

You will expand your role as a pharmacist beyond dispensing medications, becoming a key player in early disease detection and health promotion”

This Postgraduate diploma in Public Health Surveillance contains the most complete and up-to-date scientific program on the market. The most important features include:

• Development of practical case studies presented by experts in Public Health Surveillance 
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies 
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection 

You will address major communicable diseases, as well as the usefulness of vaccines in the prevention of immunopreventable infectious diseases, through TECH's extensive library of multimedia resources”

The program’s teaching staff includes professionals from the sector who contribute their work experience to this program, as well as renowned specialists from leading societies and prestigious universities. 

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive education programmed to prepare for real situations. 

This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise during the course. For this purpose, the students will be assisted by an innovative interactive video system created by renowned and experienced experts. 

Bet on TECH! As a pharmacist, you will strengthen your skills in clinical research and the application of evidence-based practices, thus contributing to the continuous improvement of Public Health"

You will interpret epidemiologic data related to environmental health and surveillance of diseases and environmental risk factors, as well as describe innovative pharmacovigilance monitoring and prevention systems"

Through specialized modules, professionals will explore key topics such as epidemiological surveillance, health risk management and evaluation of prevention programs.  In addition, the identification and control of communicable and non-communicable diseases, as well as the importance of pharmacovigilance for the early detection of drug-related adverse events will be discussed. The interpretation of epidemiological data will also be addressed, the implementation of evidence-based strategies and collaboration in international disease surveillance systems.

With a comprehensive and up-to-date approach, this program will empower you to play a vital role in promoting Public Health and disease prevention in your communities”

Module 1. Public Health Monitoring 

1.1. Public Health Protection, Prevention and Surveillance: Classification, Evaluation, Management, Control and Risk Communication 

1.1.1. Health Protection and Prevention 
1.1.2. Health Surveillance and Risk Management 
1.1.3. Risk Communication. Mechanisms and Limitations 

1.2. Self-control and Surveillance Systems: Hazard Analysis and Critical Control Points 

1.2.1. Establishment of Preventive Protocols 
1.2.2. Risk Identification and Assessment 
1.2.3. Implementation and Follow-up. Control Points 

1.3. Research and Critical Analysis of Process and Result Indicators, Records, and Evaluation Systems Development and Innovation 

1.3.1. Research and Analysis of Indicators 
1.3.2. Recording and Evaluation for Efficient Data Management 
1.3.3. Innovation in Evaluation Systems 

1.4. Research in the Design, Implementation, and Impact Evaluation of Health Protection and Prevention Programs 

1.4.1. Mechanisms for the Design of Health Protection and Prevention Programs 
1.4.2. Implementation of Health Protection and Prevention Programs
1.4.3. Analysis of the Impact of Health Protection and Prevention Programs 

1.5. Analysis and Interpretation of Epidemiological Data on Environmental Health: Surveillance, Estimation, Plans and Programs 

1.5.1. Importance of Environmental Health in Human Health 
1.5.2. Exploration of Environmental Epidemiological Data 
1.5.3. Practical Application of Environmental Data Analysis 

1.6. Interpretation of Epidemiological Data on Chronic Diseases and Planning: Surveillance, Estimation, Plan Design, Programs and Screening 

1.6.1. Epidemiological Analysis of Chronic Diseases. Importance of Follow-up 
1.6.2. Design and Development of Interventions for Chronic Diseases 
1.6.3. Epidemiological Surveillance and Disease Load Analysis 

1.7. Research in Primary Prevention of Chronic Diseases: Health Protection 

1.7.1. Research in Primary Prevention of Chronic Diseases 
1.7.2. Applied Research in Prevention and Health Protection 
1.7.3. Impact Evaluation and Communication of Results 

1.8. Innovation in Pharmacovigilance Monitoring and Prevention Systems: Alerts and Preventive Interventions 

1.8.1. Importance of Pharmacovigilance. Safety in the Use of Medications 
1.8.2. Advances in Pharmacovigilance Monitoring Systems 
1.8.3. Risk Prevention through Preventive Interventions 

1.9. Models of Response to Alerts, Epidemic Outbreaks and Emergencies Development of Protocols and Procedures 

1.9.1. Response Strategies for Health Emergencies 
1.9.2. Development of Crisis Management Protocols 
1.9.3. Implementation and Evaluation of Emergency Response 

1.10. International Health and Innovation in International Cooperation for Epidemiological Surveillance 

1.10.1. International Health Global Perspective on Epidemiological Surveillance 
1.10.2. Innovation in International Cooperation for Epidemiological Surveillance 
1.10.3. Challenges and Future of International Health Cooperation

Module 2. Epidemiology and Prevention of Communicable and Non-Communicable Diseases

2.1. Epidemiology of Cancer: Risk Factors and Prevention Primary 

2.1.1. Descriptive Epidemiology: Incidence, Mortality and Data Sources 
2.1.2. Cancer Risk Factors: Environmental and Occupational  
2.1.3. Other Factors: Ultraviolet Light, Infections, Radiations 

2.2. Risk Factors and Primary Prevention of Cancer: Lifestyle and Screening  

2.2.1. Primary Prevention. Risk Factors and Prevention Strategies 
2.2.2. Legislative Measures 
2.2.3. Secondary Prevention 

2.3. Biological Mechanisms of Cardiovascular Diseases. Estimation of Cardiovascular Risk and Population Prevention. 

2.3.1. Ischemic Heart Disease and Stroke 
2.3.2. Epidemiological Indicators 
2.3.3. Classification of Cardiovascular Risk  
2.3.4. Prevention and Control of Cardiovascular Diseases 

2.4. Detection of Rare Diseases and Neonatal Screening 

2.4.1. Rare Diseases 
2.4.2. Newborn Screening Programs 
2.4.3. Neonatal Screening for Congenital Metabolic and Endocrinologic Diseases 

2.5. Comprehensive Approach to Chronic Disease Prevention for Healthy and Sustainable Aging 

2.5.1. Healthy Aging 
2.5.2. Active Aging 
2.5.3. Integrated Prevention 

2.6. Epidemiology of Communicable Diseases: Epidemiological Surveillance Systems and Notifiable Diseases Systems 

2.6.1. Causative Agents  
2.6.2. Time Periods  
2.6.3. Transmission  
2.6.4. Host and Susceptible Population  
2.6.5. Epidemiological Surveillance Systems 

2.7. Utility of Vaccines in the Prevention of Immuno-Preventable Infectious Diseases 

2.7.1. Analysis of the Importance of Vaccination in the Prevention of Infectious Diseases at the Individual and Community Levels 
2.7.2. Evolution of Vaccines:  Types of Vaccines Currently Available 
2.7.3. Mechanisms of Action of Vaccines and Their Impact on the Immune System 
2.7.4. Efficacy and Safety of Vaccines in the Prevention of Infectious Diseases 
2.7.5. Importance of Vaccination in Risk Groups and in the Prevention of Epidemics 
2.7.6. Logistics and Vaccination Programs at the International Level 
2.7.7. Economic and Social Impact of Vaccination in the Prevention of Infectious Diseases 
2.7.8. Research and Analysis of Barriers and Challenges in the Implementation of Vaccination Programs 
2.7.9. Strategies and Measures to Promote Vaccination and Raise Public Awareness of its Importance 
2.7.10 Evaluation and Critical Analysis of the Scientific Literature Related to Vaccines and their Usefulness in the Prevention of Infectious Diseases 

2.8. Emerging Diseases. Epidemic Outbreaks 

2.8.1. Factors Favoring Emerging Diseases 
2.8.2. New Agents and Diseases 
2.8.3. International Health Regulations (IHR) 
2.8.4. Epidemic Outbreaks. Study, Control and Measures: Chemoprophylaxis, Immunoglobulins and Vaccines.  

2.9. Viral Hepatitis, HIV infection, AIDS, Sexually Transmitted Infections (STIs) and Tuberculosis 

2.9.1. Hepatitis A: Etiology, Epidemiology and Preventive Measures 
2.9.2. Hepatitis B: Etiology, Epidemiology and Preventive Measures 
2.9.3. Other Viral Hepatitis: Etiology, Epidemiology and Preventive Measures 
2.9.4. HIV: Etiology, Epidemiology and Preventive Measures 
2.9.5. Sexually Transmitted Infections (STIs): Etiology, Epidemiology, Epidemiology and Preventive Measures 
2.9.6. Tuberculosis: Etiology, Epidemiology and Preventive Measures 

2.10. Meningococcal Disease (MD) and Zoonosis: Epidemiology. Prevention and Control 

2.10.1. Epidemiology of Meningococcal Disease 
2.10.2. Prevention and Control of Meningococcal Disease 
2.10.3. Epidemiology of Zoonoses 
2.10.4. Prevention and Control of Zoonoses

Module 3. Clinical Epidemiology

3.1. Design and Quality Assessment of Intervention Studies in Epidemiology 

3.1.1. Intervention Studies, Types and Key Elements of Design 
3.1.2. Ethical Aspects of Intervention Research 
3.1.3. Design of Specific intervention Studies 
3.1.4. Tools for Assessing the Quality of Intervention Studies 
3.1.5. Critical Appraisal of Intervention Studies 
3.1.6. Importance of Design and Quality Assessment 

3.2. Pragmatic vs. Explanatory Randomized Clinical Trials 

3.2.1. Differentiation between Pragmatic and Explanatory Clinical Trials 
3.2.2. Ethical Implications of Each Approach 
3.2.3. Critical Appraisal of the Methodology and Design of Each Type of Trial 
3.2.4. Application of Knowledge to Clinical Practice and Research 
3.2.5. Encouragement of Critical Thinking and Analytical Skills 
3.2.6. Design and Execution of Clinical Trials 

3.3. Design of Diagnostic Test Studies 

3.3.1. Selection of the Study Population and Definition of the Inclusion and Exclusion Criteria 
3.3.2. Determination of the Study Design and Selection of the Reference Methodology 
3.3.3. Calculation of Diagnostic Accuracy and Analysis of the Results 

3.4. Evaluation of Quality of a Diagnostic Test Study 

3.4.1. Study Validity Analysis 
3.4.2. Evaluation of the Accuracy of the Diagnostic Test 
3.4.3. Analysis of the Clinical Utility of the Diagnostic Test 

3.5. Design and Quality Assessment of Prognostic Factors Studies 

3.5.1. Selection and Definition of Prognostic Factors 
3.5.2. Study Design and Selection of the Study Population 
3.5.3. Evaluation of the Quality of the Study and the Prognostic Model 

3.6. Evidence-Based Clinical Recommendations: GRADE 1 

3.6.1. Systematic Reviews of Scientific Literature. Identification of Clinical Recommendations 
3.6.2. Quality of Evidence and Strength of Recommendations 
3.6.3. Clinical Recommendations Applicable to Clinical Practice 
3.6.4. Development of a Clinical Protocol or Clinical Guideline based on the Recommendations Identified 
3.6.5. Implementation and Follow-up of the Clinical Protocol or Guideline in Patient Care Evidence and Focus on Improving Clinical Outcomes 
3.6.6. Periodic Evaluation, through Monitoring of Clinical Outcome Indicators and Feedback to the Health Professionals Involved 

3.7. Evidence-Based Clinical Recommendations: GRADE 2 

3.7.1. Analysis and Synthesis of the Evidence Available in the Scientific Literature for the Development of Recommendations 
3.7.2. Identification and Evaluation of the Quality of the Relevant Studies Supporting the Clinical Recommendations 
3.7.3. Application of the Principles of the GRADE Methodology to Establish the Strength and Certainty of Clinical Recommendations 
3.7.4. Developing Clinical Practice Guidelines that Incorporate Evidence-Based Recommendations and are Useful for Decision-Making 
3.7.5. Regular Updating and Revision of Clinical Recommendations Based on Available Scientific Evidence 

3.8. Evaluation of the Quality of Care 

3.8.1. Quality Criteria and Standards from a Safety Point of View 
3.8.2. Evaluation from the Point of View of the Effectiveness of the Results Obtained through the Actions Evaluated and Their Components 
3.8.3. Measurement of Patient Outcomes and Experiences, Patient-Reported Outcome Measures (PROM) and Patient-Reported Experience Measures (PREM) 
3.8.4. Indicators for Assessing the Degree of Involvement, Participation and Satisfaction of Health Professionals 

3.9. Incorporation of Patient Values and Preferences: Shared Decisions 

3.9.1. Effective Communication and Understanding of Values and Preferences 
3.9.2. Education and Counseling on Treatment Options 
3.9.3. Facilitation of Shared Decision Making 

3.10. Patient Safety 

3.10.1. Identification and Recording of Adverse Events 
3.10.2. Analysis of Errors and Underlying Causes 
3.10.3. Implementation of Corrective Actions and Prevention Measures

This program will be vital for pharmacists seeking to broaden their understanding of disease prevention and management, both communicable and noncommunicable”